Duloxetine in Adults With ADHD: A Randomized, Placebo-Controlled Pilot Study

Journal of Attention Disorders

Volumn 18, Issue 2, 2014, Pages 169-175

  Bilodeau, Mathieu ^a   Simon, Tarek ^b   Beauchamp, Miriam H ^a,c   Lespérance, Paul ^a,d   Dubreucq, Simon ^a   Dorée, Jean Pierre ^e   Tourjman, Smadar Valérie ^a,f  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e Centre Hospitalier Pierre Legardeur   (Canada)

^f CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

Author keywords

ADHD; adult; cymbalta; duloxetine; nonstimulant

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE; THIOPHENE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; MIDDLE AGED; NONSTIMULANT; PERSONALITY TEST; PILOT STUDY; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADHD; ADULT; CYMBALTA; DULOXETINE; NONSTIMULANT;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; THIOPHENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891875808     PISSN: 10870547     EISSN: 15571246     Source Type: Journal    
DOI: 10.1177/1087054712443157     Document Type: Article

References (28)

1. Allen A. J.,Kurlan R. M.,Gilbert D. L.,Coffey B. J.,Linder S. L.,Lewis D. W. Spencer T. J.Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.Neurology. 2005;65:1941-1949.
2. Diagnostic and statistical manual of mental disorders. 1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.Washington, DC: Author; 1994:.
3. Diagnostic and statistical manual of mental disorders. 2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author.Washington, DC: Author; 2000:.
4. Bitter I.,Filipovits D.,Czobor P.Adverse reactions to duloxetine in depression.Expert Opinion on Drug Safety. 2011;10:839-850.
5. Brunton S.,Wang F.,Edwards S. B.,Crucitti A.,Ossanna M.,Walker D,Robinson M. J.Profile of adverse events with duloxetine treatment: A pooled analysis of placebo-controlled studies.Drug Safety. 2010;33:393-407.
6. ConnersC. K.ErhardtD.SparrowE. (1999). Conners' Adult ADHD Rating Scales (CAARS). Unpublished manuscript, North Tonawanda, NY: Multi-Health Systems.
7. Findling R. L.,Schwartz M. A.,Flannery D. J.,Manos M. J.Venlafaxine in adults with attention-deficit/hyperactivity disorder: An open clinical trial.Journal of Clinical Psychiatry. 1996;57:184-189.
8. Gao K.,Kemp D. E.,Fein E.,Wang Z.,Fang Y.,Ganocy S. J.,Calabrese J. R.Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics.Journal of Clinical Psychiatry. 2011;72:1063-1071.
9. Hamilton M.The assessment of anxiety states by rating.British Journal of Medical Psychology. 1959;32:50-55.
10. Hamilton M.A rating scale for depression.Journal of Neurology, Neurosurgery and Psychiatry. 1960;23:56-62.
11. Karpa K. D.,Cavanaugh J. E.,Lakoski J. M.Duloxetine pharmacology: Profile of a dual monoamine modulator.CNS Drug Reviews. 2002;8:361-376.
12. Kessler R. C.,Adler L. A.,Gruber M. J.,Sarawate C. A.,Spencer T.,Van Brunt D. L.Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members.International Journal of Methods in Psychiatric Research. 2007;16:52-65.
13. Kessler R. C.,Adler L.,Barkley R.,Biederman J.,Conners C. K.,Demler O,Zaslavsky A. M.The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication.American Journal of Psychiatry. 2006;163:716-723.
14. Mahmoudi-Gharaei J.,Dodangi N.,Tehrani-Doost M.,Faghihi T.Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: An open-label study.Human Psychopharmacology. 2011;26:155-160.
15. Maidment I.The use of antidepressants to treat attention deficit hyperactivity disorder in adults.Journal of Psychopharmacology. 2003;17:332-336.
16. Mancini M.,Perna G.,Rossi A.,Petralia A.Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: A review of the literature.Expert Opinion on Pharmacotherapy. 2010;11:1167-1181.
17. Meszaros A.,Czobor P.,Balint S.,Komlosi S.,Simon V.,Bitter I.Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): A meta-analysis.International Journal of Neuropsychopharmacology. 2009;12:1137-1147.
18. Mohammadi M.,Akhondzadeh S.Pharmacotherapy of attention-deficit/hyperactivity disorder: Nonstimulant medication approaches.Expert Review of Neurotherapeutics. 2007;7:195-201.
19. CGI (Clinical Global Impression) Scale.Psychopharmacology Bulletin. 1985;21:839-844.
20. Niederhofer H.Duloxetine may improve some symptoms of attention-deficit/hyperactivity disorder.Primary Care Companion to the Journal of Clinical Psychiatry. 2010a;12 (2): e1-e2.
21. Niederhofer H.First preliminary results of a single case report: Duloxetine might improve some symptoms of attention-deficit hyperactivity disorder.European Psychiatry. 2010b;25:214-215.
22. Pary R.,Lewis S.,Matuschka P. R.,Rudzinskiy P.,Safi M.,Lippmann S.Attention deficit disorder in adults.Annals of Clinical Psychiatry. 2002;14 (2): 105-111.
23. Santosh P. J.,Sattar S.,Canagaratnam M.Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.CNS Drugs. 2011;25:737-763.
24. Seixas M.,Weiss M.,Mller U.Systematic review of national and international guidelines on attention-deficit hyperactivity disorder.Journal of Psychopharmacology. 2011;:.
25. Sheehan D. V.,Lecrubier Y.,Sheehan K. H.,Amorim P.,Janavs J.,Weiller E, Dunbar G. C.The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.Journal of Clinical Psychiatry. 1998;59:22-33.
26. Shelton R. C.,Andorn A. C.,Mallinckrodt C. H.,Wohlreich M. M.,Raskin J.,Watkin J. G.,Detke M. J.Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression.International Clinical Psychopharmacology. 2007;22:348-355.
27. Tourjman S.,Bilodeau M.Improvement with duloxetine in an adult ADHD patient.Journal of Attention Disorders. 2009;13:95-96.
28. WechslerD. (1999). Manual for the WASI. Unpublished manuscript, San Antonio, TX: Psychological Corporation.